Table 1_Mepolizumab for hypereosinophilic syndrome: effectiveness and safety from real-world evidence.docx

Hypereosinophilic syndrome (HES) is a rare condition characterized by elevated eosinophil levels and related symptoms of eosinophil-mediated organ damage. We reviewed the effectiveness and safety of mepolizumab for the treatment of HES. A scoping review was conducted following the PRISMA Scoping Reviews Checklist to identify real-world evidence of mepolizumab use in HES. In total, 36 references were identified as relevant and selected for review. Overall, 105 patients previously treated with glucocorticoids received mepolizumab at different dosages (range: 100–750 mg), routes of administration (subcutaneous/intravenous), and schedules (every 2–12 weeks). Remission rates were 57.1–76.0%. Most studies reported a range of 71.4–99.1% reduction in mean blood eosinophil counts with mepolizumab treatment. In addition, a glucocorticoid-sparing effect was observed; 85.7% of patients discontinued glucocorticoids after 12 months of mepolizumab administration. Mepolizumab was considered safe and well-tolerated and severe adverse events were rare. Mepolizumab provided clinically significant benefits in patients with HES in a real-world setting.

嗜酸性粒细胞增多综合征（Hypereosinophilic syndrome, HES）是一种罕见病症，以嗜酸性粒细胞水平升高及嗜酸性粒细胞介导的器官损伤相关症状为特征。本研究针对美泊利单抗（mepolizumab）治疗嗜酸性粒细胞增多综合征的有效性与安全性展开回顾分析。本研究遵循《PRISMA范围综述检查表》（PRISMA Scoping Reviews Checklist）开展范围综述，旨在检索美泊利单抗用于嗜酸性粒细胞增多综合征治疗的真实世界证据。最终共筛选出36篇相关文献纳入综述。整体而言，105名曾接受糖皮质激素治疗的患者接受了不同剂量（100~750mg）、给药途径（皮下/静脉）及给药方案（每2~12周一次）的美泊利单抗治疗。患者的缓解率达57.1%~76.0%。多数研究显示，经美泊利单抗治疗后，患者外周血嗜酸性粒细胞平均计数可降低71.4%~99.1%。此外，研究观察到美泊利单抗具有糖皮质激素节省效应：85.7%的患者在接受12个月美泊利单抗治疗后可停用糖皮质激素。美泊利单抗安全性良好、耐受性佳，严重不良事件发生率极低。在真实世界临床场景中，美泊利单抗可为嗜酸性粒细胞增多综合征患者带来具有临床意义的获益。